Pharmacotherapy for metabolic dysfunction-associated steatohepatitis: heart-liver co-management

Hepatology

Best buys for metabolic dysfunction-associated steatotic liver disease and metabolic dysfunction-associated steatohepatitis: a global Delphi study

Lancet Gastroenterol Hepatol

Lazarus JV, Agirre-Garrido L, White TM, Arora AK, Manolas MI, Diaz LA, Arab JP, Zelber-Sagi S, Alkhouri N, Spearman CW, Schattenberg JM, Kondili LA, Carrieri P, Lofton HF, Jaisinghani P, Kumar S, Duseja A, El-Kassas M, Takahasi H, Shawcross DL, Stine JG, Villota-Rivas M, Miralles-Sanchez JE, Pannain S, Brennan PN, MASLD/MASH Collaborators

doi: 10.1016/S2468-1253(25)00300-0

Hepatology

Risk of hepatic and extrahepatic outcomes associated with metabolic dysfunction-associated steatotic liver disease and metabolic dysfunction and alcohol-associated steatotic liver disease: a systematic review and meta-analysis

Lancet Gastroenterol Hepatol

Celsa C, Pennisi G, Tulone A, Ciancimino G, Vaccaro M, Pecorella F, Di Maria G, Enea M, Midiri F, Mantovani A, Targher G, Krag A, Rinella ME, Cammà C, Petta S

doi: 10.1016/S2468-1253(25)00188-8

Hepatology

Efficacy and safety of zalfermin co-administered with semaglutide in participants with fibrosis and cirrhosis due to metabolic dysfunction-associated steatohepatitis: a phase 2, dose-ranging, double-blind, randomised controlled trial

Lancet Gastroenterol Hepatol

Loomba R, George J, Castera L, Francque S, Lawitz E, Shoeb A, Clausen JO, Andersen B, Larsen AB, Gluud LL

doi: 10.1016/S2468-1253(26)00123-8

Hepatology

Mediterranean Diet Adherence Is Associated With Reduced Liver Fibrosis Risk in Metabolic Dysfunction-Associated Steatotic Liver Disease

J Gastroenterol Hepatol

Hsieh ML, Su TH, Lin YC, Chen YY, Tung CF, Huang LS, Wu CH, Peng YC, Hsieh VC

doi: 10.1111/jgh.70259

Hepatology

Comparative efficacy of different diet modalities on metabolic profiles and liver functions in metabolic dysfunction-associated fatty liver disease: a network meta-analysis

BMC Gastroenterol

Zou J, Tian F, Cui S, Hou J, Li Z, Wei Y, Cui H, Li Y, Zhou S, He Z, Ma X

doi: 10.1186/s12876-025-04535-1

Further Publications

Clinical Care Pathway for the Risk Stratification and Management of Patients with Metabolic Dysfunction-Associated Steatotic Liver Disease

Gastroenterology

Kanwal F, Bril F, Wai-Sun Wong V, Adams LA, Pfotenhauer K, Skolnik N, Wright EE Jr, Eckel RH, Noureddin M, Loomba R, Allen AM, Bansal MB, Godwin KM, El-Serag HB, Shubrook JH

doi: 10.1053/j.gastro.2026.01.047

Further Publications

Association between the PNPLA3 I148M (rs738409) polymorphism and risk of metabolic dysfunction-associated steatotic liver disease: a meta-analysis (2015-2025)

BMC Gastroenterol

Hamood M, Al-Salehi MA, Hussein AF, Naji KM, Rawal R

doi: 10.1186/s12876-026-05160-2

Gastrointestinal CancerHepatology

Colorectal cancer in metabolic dysfunction-associated steatotic liver disease: an international Delphi consensus statement

Gut

Wu CT, Targher G, Byrne CD, Younossi ZM, Armstrong MJ, Luu HN, Lesmana CRA, Rustgi VK, Thomas JA, Okabayashi K, Lee JWJ, El-Serag HB, Kim W, Zhang HJ, Lonardo A, Souza M, George ES, Yang W, Yilmaz Y, Papatheodoridis G, Sookoian S, Romero-Gómez M, Sebastiani G, Schattenberg JM, El-Kassas M, Chan WK, Ocama P, Lupșor-Platon M, Perera N, Alswat K, Méndez-Sánchez N, Wong VW, Chai J, Tilg H, Sung JJ, Zheng MH

doi: 10.1136/gutjnl-2025-337374

Hepatology

Updated Global Consensus Recommendations for Risk Stratification, Treatment Initiation, and Response Monitoring in Metabolic Dysfunction-Associated Steatotic Liver Disease

Clin Gastroenterol Hepatol

Younossi ZM, Kalligeros M, Wong VW, Al-Naamani KM, Tacke F, Tsochatzis E, Crespo J, El-Kassas M, Bril F, Arrese M, Caussy C, Spearman CW, Gastaldelli A, Pessoa MG, Gadano A, Shubrook JH, Duseja A, Eguchi Y, Chan WK, Fan JG, Holleboom AG, Yu ML, Kim J, Kawaguchi T, Villela-Nogueira C, Oliveria CP, Pik-Shan Kong A, Lam B, Giles H, Betel M, Ong J, Burra P, Yilmaz Y, Pearlman B, Buti M, Papatheodoridis G, Abreu ES, Abdelmalek M, Alkhouri N, Nader F, Stepanova M, Racila A, Paik J, Wajcman DI, Grinshpan LS, Roberts SK, Alqahtani SA, Zelber-Sagi S, Castera L, Henry L

doi: 10.1016/j.cgh.2026.03.030

Related content

Best buys for metabolic dysfunction-associated steatotic liver disease and metabolic dysfunction-associated steatohepatitis: a global Delphi study

Risk of hepatic and extrahepatic outcomes associated with metabolic dysfunction-associated steatotic liver disease and metabolic dysfunction and alcohol-associated steatotic liver disease: a systematic review and meta-analysis

Efficacy and safety of zalfermin co-administered with semaglutide in participants with fibrosis and cirrhosis due to metabolic dysfunction-associated steatohepatitis: a phase 2, dose-ranging, double-blind, randomised controlled trial

Mediterranean Diet Adherence Is Associated With Reduced Liver Fibrosis Risk in Metabolic Dysfunction-Associated Steatotic Liver Disease

Comparative efficacy of different diet modalities on metabolic profiles and liver functions in metabolic dysfunction-associated fatty liver disease: a network meta-analysis

Clinical Care Pathway for the Risk Stratification and Management of Patients with Metabolic Dysfunction-Associated Steatotic Liver Disease

Association between the PNPLA3 I148M (rs738409) polymorphism and risk of metabolic dysfunction-associated steatotic liver disease: a meta-analysis (2015-2025)

Colorectal cancer in metabolic dysfunction-associated steatotic liver disease: an international Delphi consensus statement

Updated Global Consensus Recommendations for Risk Stratification, Treatment Initiation, and Response Monitoring in Metabolic Dysfunction-Associated Steatotic Liver Disease